Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma Academic Article uri icon

Overview

MeSH Major

  • Biological Products
  • Salvage Therapy
  • Urologic Neoplasms
  • Urothelium

abstract

  • CR occurs in 1.8% of patients receiving salvage therapy for advanced UC and is strongly associated with durable OS and PFS. CR warrants validation as an intermediate end point and may help select agents for further investigation and tumors for molecular interrogation.

publication date

  • April 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.clgc.2014.09.004

PubMed ID

  • 25458370

Additional Document Info

start page

  • 185

end page

  • 92

volume

  • 13

number

  • 2